Markets
BSE See NSE See 52,588.71
14.25 (0.03%)

Strides Pharma slumps despite getting nod from USFDA for Ursodiol capsules

chinmayee d
/ Categories: Mindshare, DSIJ News
Rate this article:
5.0
Strides Pharma slumps despite getting nod from USFDA for Ursodiol capsules

The global pharmaceutical company, Strides Pharma announced on Monday that its step-down wholly-owned subsidiary, Strides Pharma Global Pte Limited (Singapore) has received approval for Ursodiol capsules USP from United States Food & Drug Administration (USFDA). 

Reacting to the news, its share rose almost 3 per cent on BSE. 

Ursodiol capsules USP, 300 mg is used in the treatment of patients with primary biliary cirrhosis (PBC). The product is bioequivalent and therapeutically equivalent to Actigall capsules, 300 mg, of Allergan Sales, LLC. The US market for the capsule is approximately USD 45 million, according to IQVIA MAT November 2020 data. 

Strides Pharma is engaged in the manufacture of pharmaceutical dosage forms in branded as well generic categories. Location-wise, its revenue mix comprises 59 per cent from North America, 19 per cent from Europe, 11 per cent from Africa, 7 per cent from Australia, 2 per cent from India, 1 per cent from Asia and 1 per cent from other markets. 

At 2.17 pm today, the share of Strides Pharma Science Limited was trading 0.61 per cent higher at Rs 852.85. It recorded an intraday high of Rs 874.8 and an intraday low of Rs 808.95 on BSE. 

Previous Article Lupin gets USFDA nod for Sevelamer Carbonate tablets; stock gains 2 per cent
Next Article Charts are never wrong, analysis is!
Please login or register to post comments.

Get A Call From Industry Experts

Send Otp

   I authorize DSIJ Pvt Ltd to contact me. This will override registry on the NDNC.

DSIJ MINDSHARE

This small-cap mega multi-bagger stock jump over 1,900 per cent in just 63 weeks

The stock has almost unchanged on an MTD basis and this could be because the stock might be consolidating after a dream run of over 1,900 per cent from the low of Rs 2.90, which was registered in the month of March last year. Besides, on a YTD basis, it’s up by almost 109 per cent.   

Karan DSIJ / Article rating: 4.1
The stock’s lifetime is at Rs 790 and it is still trading way below its all-time high, which was seen in the year 2007. Technically, the...
First246Last

Knowledge

124Last